The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice

2014 ◽  
Vol 64 (5) ◽  
pp. 609-615 ◽  
Author(s):  
Emad A Rakha ◽  
Jane Starczynski ◽  
Andrew H S Lee ◽  
Ian O Ellis
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Critical Review ◽  
Routine Practice ◽  
Her2 Testing

scholarly journals Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer

2021 ◽  
Vol 41 (8) ◽  
pp. 4143-4149
Author(s):  
MAI YAMADA ◽  
MAKOTO KUBO ◽  
HIDETAKA YAMAMOTO ◽  
NAMI YAMASHITA ◽  
MASAYA KAI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Her2 Testing

scholarly journals Complete Breast MRI Response to Neoadjuvant Chemotherapy and Prediction of Pathologic Complete Response

2019 ◽  
Vol 1 (3) ◽  
pp. 217-222 ◽  
Author(s):  
Christina A Chen ◽  
Jessica H Hayward ◽  
Genevieve A Woodard ◽  
Kimberly M Ray ◽  
Christopher J Starr ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Invasive Breast Cancer ◽  
Pathologic Complete Response ◽  
Breast Mri ◽  
Complete Response ◽  
Routine Practice ◽  
Fisher Exact Test ◽  
Tumor Subtype ◽  
Background Parenchymal Enhancement

Abstract Objective To assess the negative predictive value (NPV) of breast MRI in detecting residual disease after neoadjuvant chemotherapy (NAC) in women with invasive breast cancer, overall and by tumor subtype. Methods An institutional review board approved retrospective study from January 2010 through December 2016 identified patients with invasive breast cancer who achieved complete MRI response to NAC, defined as the absence of residual enhancement in the tumor bed above background parenchymal enhancement. During the study period, it was our routine practice to assign a BI-RADS 1 or 2 assessment to these cases. The NPV was defined as the ability of a complete MRI response to predict pathologic complete response (pCR) at final surgical pathology. Statistical analyses were performed using a Fisher exact test. Results Among 244 patients who underwent MRI to assess NAC response, 38 (16%) were determined to have complete MRI response by the interpreting radiologist. Of these, 20/38 (53%) had pCR. Complete MRI response did not significantly predict pCR for the total group (P < 0.9). However, NPVs significantly varied by molecular subtype (P < 0.004). True negative MRIs by tumor subtype were 2/10 (20%) for hormone receptor (HR)+/HER2–, 3/10 (30%) for HR+/HER2+, 6/8 (75%) for HR–/HER+, and 9/10 (90%) for triple negative (TN) subtypes. Complete MRI response significantly predicted pCR for only the TN subtype (NPV 90%; P < 0.02). Conclusions In patients with complete MRI response, 53% had pCR. While MRI lacks sufficient NPV to obviate the need for surgical excision, it may add prognostic value for certain molecular subtypes. The TN subtype demonstrated the highest NPV.

scholarly journals Indicator measures er/pr and her2 testing among women with invasive breast cancer

2013 ◽  
Vol 20 (1) ◽  
Author(s):  
C. Sandoval ◽  
R. Rahal ◽  
T. Forte ◽  
J. Klein–Geltink ◽  
D. He ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Her2 Testing
Sign in / Sign up

Export Citation Format

Share Document